Company
United StatesPublic company, NASDAQ: LINLinde Inc. (NASDAQ: LIN), Wilmington, CA – FDA Inspections
Inspection records and compliance data for Linde Inc. in Wilmington, California. 2 FDA inspections on record, last inspected July 15, 2026. Publicly traded as NASDAQ: LIN.
Company Profile
This profile covers Linde Inc. based in Wilmington, California, United States.
FDA Inspection History
- FDA inspections
- 2
- OAI
- 0
- VAI
- 0
- NAI
- 2
- Form 483s
- 0
- Warning letters
- 0
First inspected November 27, 2013. Last inspected July 15, 2026.
FDA inspections (2)
| Date | Result | FDA center(s) | Insp. # |
|---|---|---|---|
| July 15, 2026 | NAI | · Drug Quality Assurance | 1327750 |
| November 27, 2013 | NAI | Human Drugs · Drug Quality Assurance | 858224 |
FDA documents
No Form 483s, Warning Letters or EIRs on record.
Related Companies (10)
Companies with similar regulatory profiles, compliance history, and operations.
Company Information
Name
Linde Inc.
Stock ticker
LIN
Exchange
NASDAQ
Share price
$522.49
Market cap
$239.9B
Price as of
November 13, 2026
FEI Number
2015973
Address
2300 E Pacific Coast Hwy, Wilmington, California 90744, United States
Country
United States
ID: aba94731-53cf-4144-8354-54ad563d0663